Numerous studies evaluating the percentage of Ki-67 in tumor cells and response to chemotherapy have been conducted in different malignancies such as non-Hodgkin lymphoma, bladder cancer, endometrial cancer, cervical cancers, neuroendocrine tumors and sarcomas [11-13]. The gene discussed is MKI67; the disease is neoplasm.